Recent Updates
Recently added Catalysts
FDMT Positive Sentiment

VIDEO: Intravitreally administered 4D-150 shows 90% reduction in wet AMD treatment burden

Tuesday, October 15, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: In a recent presentation at the Euretina congress, Dr. Anat Loewenstein discussed the promising results of 4D-150, a gene therapy for wet age-related macular degeneration (AMD). The phase 2 PRISM trial demonstrated that a single injection of 4D-150 can reduce the treatment burden by nearly 90% for patients previously reliant on multiple anti-VEGF injections. This advancement offers hope for more effective management of wet AMD.
Price reaction · baseline $9.07 (2024-10-15T15:37:00.000Z) · hit during market hours · clean, no other FDMT news in the window
day 0 close · peak
-2%

Market Sentiment Analysis

POSITIVE FACTORS

  • 4D-150 shows a significant reduction in treatment burden for wet AMD.
  • The therapy stabilizes the disease without frequent injections.
  • It is a promising advancement in gene therapy for patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration

Full Press Release Details

Purpose-built for physicians

Read more

• LinkedIn
• Facebook
• X (Twitter)
• Bluesky
• Threads
• Email
• Copy Link
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Anat Loewenstein, MD, MHA , speaks about 4D-150 , a novel intravitreally administered gene therapy for wet age-related macular degeneration.
“We all like genetic treatment that is given intravitreally and does not necessitate subretinal therapy,” she said.
In the phase 2 PRISM trial , a single injection of 4D-150 (4D Molecular Therapeutics) given to patients previously treated with multiple anti-VEGF injections was able to reduce the treatment burden by almost 90%.
“It is very promising for our patients to have a treatment that will be able to [stabilize their] disease without the need for extremely frequent injections,” Loewenstein said.

Sources/Disclosures

Source:

Loewenstein A. Update on gene therapy for neovascular AMD. Presented at: Euretina congress; Sept. 19-22, 2024; Barcelona, Spain.
Disclosures: Loewenstein reports consulting for 4D Molecular Therapeutics.
Ask a clinical question and tap into Healio AI's knowledge base.
• PubMed, enrolling/recruiting trials, guidelines
• Clinical Guidance, Healio CME, FDA news
• Healio's exclusive daily news coverage of clinical data
Read more about

Related Content

Frequently Asked Questions

What is 4D-150?

4D-150 is a novel intravitreally administered gene therapy for wet AMD.

What were the results of the phase 2 PRISM trial?

The trial showed that a single injection of 4D-150 reduced treatment burden by almost 90%.

Who presented the findings on 4D-150?

Dr. Anat Loewenstein presented the findings at the Euretina congress.

How does 4D-150 benefit patients?

It stabilizes the disease without the need for frequent injections.

ShareAdd on Google
Tags: FDMT Viatris Investor Conferences Healthcare 4D Molecular Therapeutics wet AMD gene therapy phase 2 trial treatment burden
Last updated: Oct 15, 2024

Biotech snapshot

Cash runway
$431M liquidity · $23M/mo burn
~18 mo
Low dilution risk
Lead asset
4D-150 IVTPhase 3
Macular Neovascularization Secondary to Age-Related Macular Degeneration →

Catalyst track record

+128%
best trade around FDMT's most recent catalyst

Peak hindsight return over a 120-day window, across 9 tracked FDA/PDUFA catalysts for FDMT.

See every catalyst's timing & PoA →